cell-therapy-public-health-congress-2019-tracks

Note:

Page 27

April 15-16, 2019 | Milan, Italy

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

YEARS

Joint Event on

PUBLIC HEALTH,

EPIDEMIOLOGY AND NUTRITION

World Congress on

CELL AND GENE THERAPY

International Conference on

Cell and Gene Therapy 2019 & Public Health Congress 2019

Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 3

THINKING INSIDE THE BOX: CENTRALIZEDVS DECENTRALIZED MANUFACTURING

Vered Caplan

Orgenesis Inc., Israel

ell therapy refers to the injection of cells to cure various diseases. Cell therapy is a rapidly growing field

in medicine that can aim to treat different diseases such as diabetes, liver diseases, immuno-oncology,

cardiology, dermatology and autoimmune disease. The cell therapy industry needs to overcome major chal-

lenges before the developed therapies can be brought to patients worldwide. There is a high demand to satisfy

patient needs and the manufacturing technology lacks the capacity to meet this urgency. In addition, there is

currently a tremendous burden of cost associated with cell and gene therapies like CART, because these treat-

ments are being manufactured at offsite CMOs. Finally, the regulatory process is long, expensive and compli-

cated. There is a great need for a custom-made approach that is tailored to the specific requirements of clients

and designed to ensure short lead times with competitive costs, in order to bring state of the art therapies to

the market. Orgenesis is establishing a one-stop-shop point of care service for hospitals to bring these thera-

pies in a cost effective, high quality and scalable manner to patients. The organization is leveraging IP, technical

expertise and know-how. The platform allows a modular cell production cGMP closed system platform for the

development of early stage products. Author’s vision is providing the pathway for cell and gene therapies to

cure disease, by furthering the research and development of technologies throughout the world.

Vered Caplan, Arch Gen Intern Med 2019, Volume 3 | DOI: 10.4066/2591-7951-C2-026

Vered Caplan was the Chief Executive Officer of Orgenesis Inc. since August 14, 2014. She has an MSc in Biomedical Engineering

from Tel-Aviv University specializing in Signal Processing; Management for Engineers from Tel-Aviv University specializing in Busi-

ness Development and a BSc in Mechanical Engineering from the Technion-Israel Institute of Technology specialized in software

and CAD systems. Throughout her managerial career, she served as CEO of several biotechnology such as: Interim (President and

CEO), since 2008, she was Chief Executive Officer of Kamedis Ltd., From 2004 to 2007, she was Chief Executive Officer of GammaCan

International Inc., During the previous five years, she has been a director of the following companies: Opticul Ltd., Inmotion Ltd.,

Nehora Photonics Ltd., Ocure Ltd., Eve Medical Ltd., and Biotech Investment Corp.

BIOGRAPHY